These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 22636820)

  • 1. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes.
    Coca SG; Ismail-Beigi F; Haq N; Krumholz HM; Parikh CR
    Arch Intern Med; 2012 May; 172(10):761-9. PubMed ID: 22636820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
    Mottl AK; Buse JB; Ismail-Beigi F; Sigal RJ; Pedley CF; Papademetriou V; Simmons DL; Katz L; Mychaleckyj JC; Craven TE
    Clin J Am Soc Nephrol; 2018 Nov; 13(11):1693-1702. PubMed ID: 30361335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.
    Perkovic V; Heerspink HL; Chalmers J; Woodward M; Jun M; Li Q; MacMahon S; Cooper ME; Hamet P; Marre M; Mogensen CE; Poulter N; Mancia G; Cass A; Patel A; Zoungas S;
    Kidney Int; 2013 Mar; 83(3):517-23. PubMed ID: 23302714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive glycemic control in type 2 diabetics at high cardiovascular risk: do the benefits justify the risks?
    Shurraw S; Tonelli M
    Kidney Int; 2013 Mar; 83(3):346-8. PubMed ID: 23446251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What matters in ADVANCE and ADVANCE-ON.
    Hamet P
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive treatment and multifactorial approach for renal protection in diabetes.
    Fioretto P; Solini A
    J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S18-21. PubMed ID: 15938027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease.
    Snyder RW; Berns JS
    Semin Dial; 2004; 17(5):365-70. PubMed ID: 15461745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.
    Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
    JAMA; 2003 Oct; 290(16):2159-67. PubMed ID: 14570951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review on urine albumin testing for early detection of diabetic complications.
    Newman DJ; Mattock MB; Dawnay AB; Kerry S; McGuire A; Yaqoob M; Hitman GA; Hawke C
    Health Technol Assess; 2005 Aug; 9(30):iii-vi, xiii-163. PubMed ID: 16095545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.
    Ismail-Beigi F; Craven TE; O'Connor PJ; Karl D; Calles-Escandon J; Hramiak I; Genuth S; Cushman WC; Gerstein HC; Probstfield JL; Katz L; Schubart U;
    Kidney Int; 2012 Mar; 81(6):586-94. PubMed ID: 22166848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses.
    Williams ME; Lacson E; Wang W; Lazarus JM; Hakim R
    Clin J Am Soc Nephrol; 2010 Sep; 5(9):1595-601. PubMed ID: 20671217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring.
    Vos FE; Schollum JB; Coulter CV; Manning PJ; Duffull SB; Walker RJ
    Nephrology (Carlton); 2012 Feb; 17(2):182-8. PubMed ID: 21883672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.
    Zoungas S; Arima H; Gerstein HC; Holman RR; Woodward M; Reaven P; Hayward RA; Craven T; Coleman RL; Chalmers J;
    Lancet Diabetes Endocrinol; 2017 Jun; 5(6):431-437. PubMed ID: 28365411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?
    Bilous R
    Diabet Med; 2008 Aug; 25 Suppl 2():25-9. PubMed ID: 18717975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of microalbuminuria in patients with type 2 diabetes mellitus.
    Jerums G; MacIsaac RJ
    Treat Endocrinol; 2002; 1(3):163-73. PubMed ID: 15799209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HbA1C Variability Is Strongly Associated with Development of Macroalbuminuria in Normal or Microalbuminuria in Patients with Type 2 Diabetes Mellitus: A Six-Year Follow-Up Study.
    Chiu WC; Lai YR; Cheng BC; Huang CC; Chen JF; Lu CH
    Biomed Res Int; 2020; 2020():7462158. PubMed ID: 32047814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
    Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
    Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decline in estimated glomerular filtration rate is associated with risk of end-stage renal disease in type 2 diabetes with macroalbuminuria: an observational study from JDNCS.
    Shimizu M; Furuichi K; Toyama T; Funamoto T; Kitajima S; Hara A; Ogawa D; Koya D; Ikeda K; Koshino Y; Kurokawa Y; Abe H; Mori K; Nakayama M; Konishi Y; Samejima KI; Matsui M; Yamauchi H; Gohda T; Fukami K; Nagata D; Yamazaki H; Yuzawa Y; Suzuki Y; Fujimoto S; Maruyama S; Kato S; Naito T; Yoshimura K; Yokoyama H; Wada T;
    Clin Exp Nephrol; 2018 Apr; 22(2):377-387. PubMed ID: 28889347
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.